GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

otilimab   Click here for help

GtoPdb Ligand ID: 11132

Synonyms: GSK-3196165 | GSK3196165 | MOR-103 | MOR103
Immunopharmacology Ligand
Compound class: Antibody
Comment: Otilimab (MOR103, GSK3196165) is a clinical stage fully human IgG1λ antibody that targets the granulocyte-macrophage colony-stimulating factor (GM-CSF; CSF2). It is being investigated as a therapeutic for inflammatory diseases. MOR103 was developed using MorphoSys' HuCAL® technology, and has been fully out-licensed otilimab to GSK. MOR103 is claimed as MOR-04357 in patent WO2006122797A2 (by BLAST peptide sequence matching) [5].
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
10783 otilimab
Synonyms Click here for help
GSK-3196165 | GSK3196165 | MOR-103 | MOR103
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 189
Other databases
GtoPdb PubChem SID 434122192
Search PubMed clinical trials otilimab
Search PubMed titles otilimab
Search PubMed titles/abstracts otilimab